Mortality in Patients with Biopsy-proven Giant Cell Arteritis: A South Australian Population-based Study

被引:47
|
作者
Ninan, Jem [1 ]
Anh-Minh Nguyen [3 ]
Cole, Antonia [1 ]
Rischmueller, Maureen [1 ]
Dodd, Thomas [4 ]
Roberts-Thomson, Peter [5 ]
Hill, Catherine L. [1 ,2 ]
机构
[1] Queen Elizabeth Hosp, Rheumatol Unit, Woodville, SA 5011, Australia
[2] Univ Adelaide, Hlth Observ, Woodville, SA, Australia
[3] Dept Hlth, Hlth Stat Unit, Woodville, SA, Australia
[4] SA Pathol, Dept Tissue Pathol, Woodville, SA, Australia
[5] Flinders Med Ctr, Dept Allergy Immunol & Arthrit, Woodville, SA, Australia
关键词
MORTALITY RATE; GIANT CELL ARTERITIS; BIOPSY-PROVEN; TEMPORAL ARTERITIS; POLYMYALGIA-RHEUMATICA; SURVIVAL;
D O I
10.3899/jrheum.101254
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To compare mortality rates and cause of death in patients with biopsy-proven giant cell arteritis (GCA) with those in the general population. Methods. Patients with biopsy-proven GCA were identified from pathology reports of temporal artery biopsies in South Australia, from January 1, 1992, to December 31, 2006. All patients with biopsy-proven GCA were linked to the South Australian Births, Death and Marriage Registry to identify deaths until December 31, 2006. Standardized mortality ratios and relative survival (ratio of observed survival in GCA group to expected survival of general South Australian population, matched by age, sex, and calendar time) were calculated. The cause of death recorded on the death certificate was also documented. Results. There were 225 cases of biopsy-proven GCA (163 women and 62 men). The mean age at diagnosis of GCA was 78.2 years. The mean followup period was 66.2 months (SD 47.1 mo). During the followup period, there were 71 deaths in the GCA group (50 women, 21 men). The standardized mortality ratio was 0.99 (95% CI 0.77-1.25). The relative survival for different followup periods demonstrates that patients with GCA experienced similar mortality to the general population (age-matched and sex-matched). Death from cardiovascular causes (45%) was the most common, followed by infection (17%) and cancer (17%). Infection was a significantly more common cause of death in the first year (chi-squared, p = 0.0002). Conclusion. Our population-based cohort study did not demonstrate any increased mortality risk for patients diagnosed with biopsy-proven GCA. The risk of death from infection early in the disease may be increased. (First Release Aug 15 2011; J Rheumatol 2011;38:2215-17; doi:10.3899/jrheum.101254)
引用
收藏
页码:2215 / 2217
页数:3
相关论文
共 50 条
  • [31] Incidence, Prevalence, and Mortality Rates of Biopsy-Proven Giant Cell Arteritis in Southern Sweden.
    Mohammad, Aladdin
    Mohammad, Jabbar
    Nilsson, Jan-Ake
    Jacobsson, Lennart T. H.
    Merkel, Peter A.
    Turesson, Carl
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S950 - S950
  • [32] MORTALITY IN GIANT-CELL ARTERITIS PATIENTS: A NATIONWIDE POPULATION-BASED STUDY
    Ben-Shabat, Niv
    Amital, Howard
    Cohen, Arnon
    Comanesther, Doron
    Tiosano, Shmuel
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 147 - 148
  • [33] Incidence of biopsy-proven giant cell arteritis (GCA) in South Australia 2014-2020
    Ninan, Jem
    Ruediger, Carlee
    Dyer, Kathryn A.
    Dodd, Thomas
    Black, Rachel J.
    Lyne, Suellen
    Shanahan, Ernst M.
    Proudman, Susanna M.
    Lester, Susan
    McNeil, Julian
    Hill, Catherine L.
    FRONTIERS IN MEDICINE, 2023, 10
  • [34] Frequency and Predictive Variables of Relapses in Patients with Biopsy-Proven Giant Cell Arteritis.
    Boiardi, Luigi
    Restuccia, Giovanna
    Muratore, Francesco
    Cavazza, Alberto
    Cimino, Luca
    Aldigeri, Raffaella
    Macchioni, Pierluigi
    Catanoso, Maria Grazia
    Pipitone, Nicolo
    Salvarani, Carlo
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S349 - S350
  • [35] Steroid therapy improves endothelial function in patients with biopsy-proven giant cell arteritis
    Gonzalez-Juanatey, C
    Llorca, J
    Garcia-Porrua, C
    Sanchez-Andrade, A
    Martín, J
    Gonzalez-Gay, MA
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (01) : 74 - 78
  • [36] NEUROLOGIC DISEASE IN BIOPSY-PROVEN GIANT-CELL (TEMPORAL) ARTERITIS
    CASELLI, RJ
    HUNDER, GG
    WHISNANT, JP
    NEUROLOGY, 1988, 38 (03) : 352 - 359
  • [37] INCIDENCE AND SURVIVAL OF BIOPSY-PROVEN GIANT CELL ARTERITIS IN NORTHERN ITALY
    Macchioni, P.
    Catanoso, M.
    Boiardi, L.
    Muratore, F.
    Restuccia, G.
    Chiarolanza, I.
    Cavazza, A.
    Luberto, F.
    Salvarani, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 620 - 620
  • [38] Risk Factors for Permanent Visual Loss in Biopsy-proven Giant Cell Arteritis: A Study of 339 Patients
    Liozon, Eric
    Dalmay, Francois
    Lalloue, Fabrice
    Gondran, Guillaume
    Bezanahary, Holy
    Fauchais, Anne-Laure
    Ly, Kim-Heang
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (07) : 1393 - 1399
  • [39] Biopsy-Proven Giant Cell Arteritis in an Urban African American Population: a Hematologic and Demographic Profile
    Katz, Matthew
    Katz, Barrett
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [40] Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis
    Font, C
    Cid, MC
    CollVinent, B
    LopezSoto, A
    Grau, JM
    BRITISH JOURNAL OF RHEUMATOLOGY, 1997, 36 (02): : 251 - 254